Transactions
29
Insider / Attovia Therapeutics, Inc.
WALSH COLIN
Director at Attovia Therapeutics, Inc.
- Company
- Attovia Therapeutics, Inc.
- Ticker
- ATTO
- First filing on record
- August 13, 2026
- Latest trade on record
- August 6, 2026
- SEC filings
- EDGAR ↗
WALSH COLIN, Director at Attovia Therapeutics, Inc., has disclosed 29 transactions in ATTO since August 13, 2026: 2 purchases (2 open-market buys) and 23 sales, worth about $12.5M at the reported prices. The latest was filed August 13, 2026, 7 days after the trade; 29 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
2
Sales
23
Avg. disclosure lag
7.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months WALSH COLIN made 2 purchases worth $10M and 23 sales worth $2.3M, plus 4 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
WALSH COLIN has traded 1 stock on record; the largest by dollars is ATTO.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 23 | 105,807 | $2.3M |
| C | Conversion of a derivative | 4 | 25,062,737 | — |
| P | Open-market purchase | 2 | 585,000 | $10.3M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 29 | 2 · $10.3M | 23 · $2.3M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ATTO | Exchange C | August 6, 2026 | August 13, 2026 | 7d | 4,445,275 | — | — | lateindirectderivative | Form 4 ↗ | |
| ATTO | Exchange C | August 6, 2026 | August 13, 2026 | 7d | 18,181,830 | — | — | lateindirectderivative | Form 4 ↗ | |
| ATTO | Buy P | August 6, 2026 | August 13, 2026 | 7d | 500,000 | $17 | $8.5M | lateindirectalso in another filing | Form 4 ↗ | |
| ATTO | Exchange C | August 6, 2026 | August 13, 2026 | 7d | 478,498 | — | — | lateindirect | Form 4 ↗ | |
| ATTO | Exchange C | August 6, 2026 | August 13, 2026 | 7d | 1,957,134 | — | — | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 76,418 | $21 | $1.6M | lateindirectalso in another filing | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 6,763 | $22 | $146K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 100 | $22 | $2,199 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 1,163 | $22 | $26K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 700 | $22 | $15K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 200 | $22 | $4,410 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 443 | $22 | $9,649 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 300 | $21 | $6,252 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 1,040 | $22 | $23K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 1,180 | $22 | $26K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 400 | $22 | $8,808 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 6,970 | $22 | $154K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 672 | $22 | $15K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 753 | $22 | $17K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 100 | $22 | $2,211 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 480 | $22 | $10K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 200 | $22 | $4,420 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 3,402 | $22 | $75K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 1,556 | $22 | $34K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 200 | $22 | $4,410 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 1,332 | $22 | $29K | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 447 | $22 | $9,776 | lateindirect | Form 4 ↗ | |
| ATTO | Sell S | August 5, 2026 | August 13, 2026 | 8d | 988 | $22 | $22K | lateindirect | Form 4 ↗ | |
| ATTO | Buy P | August 5, 2026 | August 13, 2026 | 8d | 85,000 | $21 | $1.8M | lateindirectalso in another filing | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 13, 2026 | Form 4 | 0001866174-26-000009 | 29 | published | EDGAR ↗ |
Other insiders at Attovia Therapeutics, Inc.
- GOLDMAN SACHS GROUP INC Insider 29 rows
- Sanofi Insider 24 rows
- Frazier Life Sciences XI, L.P. Insider 9 rows
- venBio Global Strategic Fund IV, L.P. Insider 7 rows
- Redmile Group, LLC Insider 4 rows
- Attovia Therapeutics, Inc. President and CEO 2 rows
- Deep Track Biotechnology Master Fund, Ltd. Insider 2 rows
- Chen Hubert Chief Medical Officer 1 row
- GOLD MITCHELL Director 1 row
- Odrowaz Zaneta Chief Business Officer 1 row
Everyone on file, with contracts and lobbying under the company's name: Attovia Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 29 | August 13, 2026 | August 13, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.